Process Safety in Pharmaceutical Operations
Preventing low-frequency, high-consequence events: hazard studies, safeguards, management of change, mechanical integrity, emergency systems, and learning from incidents and near misses. Process safety failures are rare and catastrophic, and their leading indicators are entirely ordinary — deferred maintenance on safety-critical equipment, bypassed interlocks, changes assessed for product impact and not for hazard. Occupational safety metrics do not detect any of them.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 22 LINKSProcess safety fails slowly and visibly: deferred maintenance, bypassed interlocks and changes assessed for product impact but not for hazard are the leading indicators, and each is individually defensible.
06 · QUALITY MATURITY — PROCESS SAFETY IN PHARMACEUTICAL OPERATIONS, REACTIVE TO ADAPTIVE
Process hazards were assessed when the plant was designed. The study is filed and the plant has changed since.
Hazard studies are performed for new installations, and modifications are assessed for product impact by change control that has no hazard question.
Change control asks the hazard question as well as the product one, and the hazard study is revalidated when the process it describes moves.
Leading indicators are watched — overdue maintenance on safety-critical equipment, active bypasses, overdue proof tests — and treated as findings.
Safety-critical equipment and its performance are managed with the same discipline as product-critical equipment, and the two share their evidence.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 5
Derived from the 5 standards SPEQ maps to this subject, across 4 regulatory bodies: ICH, ASTM, IEC, ISO.
RECORDS & OBJECTIVE EVIDENCE
- Hazard studies covering the process as it currently exists
- Change records showing hazard assessed alongside product impact
- The safety-critical equipment register, with maintenance and testing status
- Bypass and override records, with authorisation and duration
- Leading indicator data and the reviews that act on it
COMMON INSPECTION FINDINGS
- A hazard study describing a process that has since been modified
- Change control assessing product impact with no hazard question
- Interlocks bypassed for operational convenience with no authorisation or expiry
- Maintenance deferred on safety-critical equipment while product-critical work proceeds
- Proof testing of protective functions overdue or undefined
Personal safety and process safety are different disciplines
A site with an excellent injury record can be approaching a major incident, and the confusion between the two has featured in the investigation of more than one industrial disaster. Personal safety concerns frequent, low-consequence events with fast feedback. Process safety concerns rare, high-consequence events with almost no feedback until they occur — which means the state of the system has to be inferred from the integrity of its barriers rather than from its outcome record.
Pharmaceutical operations carry genuine process-safety hazards that are easy to under-recognise because the industry does not think of itself as heavy process industry: solvent handling and flammable atmospheres, exothermic reactions and runaway potential, dust explosion in solids handling, high-pressure and cryogenic systems, and reactive chemistry in API manufacture.
Barriers only count if their integrity is maintained
Layer-of-protection analysis credits independent barriers, and IEC 61511 requires a safety instrumented function to deliver a defined integrity level, maintained through proof testing at defined intervals. A barrier whose proof tests have lapsed no longer delivers the integrity credited to it, which means the risk assessment that relied on it is no longer valid either — quietly, and without anything having failed.
That is why deferred maintenance on safety-critical equipment is a process-safety leading indicator rather than a maintenance backlog item, and why the safety-critical subset of the maintenance schedule deserves separate visibility. A single overdue proof test is information about an assessment, not just about a work order.
Management of change has to ask the hazard question
A regulated site’s change control is built to assess product impact, and it is good at it. A change that alters process safety — a solvent substitution changing flammability, an increased batch size changing thermal mass, a modified sequence changing the maximum accumulation of a reactive intermediate — may pass a product-impact assessment cleanly while altering the hazard picture the original hazard study assumed.
The fix is a hazard-impact question in the same change-control form, with a defined trigger for re-running the hazard study. Sites that have both processes but not the trigger discover the gap when a hazard study is revisited years later and no longer describes the plant.
SPEQ interpretation — near misses are the only signal available
Because major process-safety events are rare, an organisation cannot learn about its exposure from its own incident record. The only available signal is the stream of things that nearly happened: an interlock that operated when it should not have needed to, a relief device that lifted, an isolation found incorrect, a bypass discovered in place.
These are recorded in engineering systems if anywhere, and are rarely aggregated or reviewed as evidence about barrier health. Building that review is the single highest-value process-safety activity available to a site that has never had an event — which is nearly all of them, and precisely why it is not prioritised.
FREQUENTLY ASKED
How does process safety differ from personal safety?
Personal safety concerns frequent, low-consequence events with fast feedback; process safety concerns rare, high-consequence events with almost no feedback until they occur. A site with an excellent injury record can be approaching a major incident, and that confusion has featured in more than one industrial disaster investigation.
Do pharmaceutical sites have real process-safety hazards?
Yes, and they are under-recognised because the industry does not think of itself as heavy process industry: solvent handling and flammable atmospheres, exothermic reactions with runaway potential, dust explosion in solids handling, high-pressure and cryogenic systems, and reactive chemistry in API manufacture.
Why is overdue proof testing a process-safety indicator?
Because a safety instrumented function whose proof tests have lapsed no longer delivers the integrity level credited to it, so the risk assessment that relied on that barrier is no longer valid — quietly, without anything having failed. A single overdue proof test is information about an assessment, not just a work order.
What does change control usually miss?
The hazard question. A solvent substitution changing flammability, a larger batch changing thermal mass, or a modified sequence changing reactive-intermediate accumulation can pass a product-impact assessment cleanly while invalidating the hazard study. A hazard-impact question in the same form, with a defined re-study trigger, is the fix.